Stockscreener 앱 받기
733.78
0.10%
0.74
시간 외 거래:
729.50
-4.28
-0.58%
전일 마감가:
$733.04
열려 있는:
$729.4
하루 거래량:
786.72K
Relative Volume:
0.81
시가총액:
$77.12B
수익:
$14.25B
순이익/손실:
$4.58B
주가수익비율:
17.57
EPS:
41.7701
순현금흐름:
$3.88B
1주 성능:
-3.31%
1개월 성능:
-4.45%
6개월 성능:
+35.25%
1년 성능:
+7.66%
1일 변동 폭
$718.38
$737.87
1주일 범위
$718.38
$766.64
52주 변동 폭
$476.49
$821.11
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
733.78 | 77.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.08 | 111.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
809.64 | 49.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.53 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.28 | 37.42B | 4.98B | 69.59M | 525.67M | 0.5197 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Seizert Capital Partners LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
(REGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Should You Be Excited for Regeneron (REGN)? - Insider Monkey
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Momentum - Yahoo Finance
Allstate Corp Makes New $2.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Expansion wave in Saratoga County, New York: Regeneron, GlobalFoundries, Soleno, LISSMAC and more - The Business Journals
Third retinal indication for Eylea 8mg approved in Europe - The Pharma Letter
Sanofi, Regeneron Can't Patent Asthma Prevention Tool - Law360
Neutralizing Antibody Market is Going to Boom, Highlighting - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ASR Vermogensbeheer N.V. - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Evergreen Capital Management LLC - MarketBeat
Howland Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 4,200 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea - MSN
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
Dillon & Associates Inc. Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Basal Cell Carcinoma Treatment Market to Reach US$ 19.6 Billion - openPR.com
Atopic Dermatitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharma, Abbvie, Allergan - Barchart.com
Trading Recap: What are the future prospects of Regeneron Pharmaceuticals IncMarket Growth Report & Weekly Market Pulse Updates - baoquankhu1.vn
Meritage Portfolio Management Buys 9,486 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Nordea Investment Management AB Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? - Yahoo Finance
JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries - Pharmaceutical Technology
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Benzinga
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail
Allergic Rhinitis Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Regeneron Pharma, Allergy Therapeutics, Inmunotek, UCB Pharma, Orexo AB, Hyloris Pharma - Barchart.com
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Erasca (ERAS) and Connect Biopharma Holdings (CNTB) - The Globe and Mail
Regeneron's Yancopoulos on Hearing Loss Gene Therapy, Weight Loss Drugs - marketscreener.com
JP Morgan 2026: Regeneron Focusing on Broad Pipeline Development - PharmExec.com
JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats - BioSpace
Regeneron Pharmaceuticals (BIT:1REGN) Price Target Increased by 11.61% to 743.10 - Nasdaq
PKO Investment Management Joint Stock Co Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Highlights Growth Strategy and Pipeline at JPM Conference - The Globe and Mail
Regeneron Pharma price target raised to $820 from $800 at Raymond James - Investing.com UK
Market Review: What is the fair value of Regeneron Pharmaceuticals Inc. stock nowBull Run & High Conviction Trade Alerts - Bộ Nội Vụ
Commonwealth Equity Services LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stop Loss: Will Regeneron Pharmaceuticals Inc. stock split attract more investorsJuly 2025 WrapUp & Safe Swing Trade Setup Alerts - Bộ Nội Vụ
Amgen Fights Regeneron’s Bid to Pause Eylea Antitrust Claims - Bloomberg Law News
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: A Strong Buy with 15.19% Return on Equity and 3.53% Potential Upside - DirectorsTalk Interviews
Regeneron announcements validate Apogee thesis, says Stifel By Investing.com - Investing.com UK
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Analyst Buy Upgrades - simplywall.st
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
First Horizon Corp Makes New $6.23 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Poised for Rapid - openPR.com
A big Wall Street flip just changed the Regeneron narrative - thestreet.com
Regeneron and Sanofi's Dupixent succeeds in late-stage study - MSN
Oregon Public Employees Retirement Fund Has $6.56 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Cerity Partners LLC - MarketBeat
What is the fair value of Regeneron Pharmaceuticals Inc. stock nowJuly 2025 Rallies & Verified Entry Point Signals - ulpravda.ru
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
1.04%
자본화:
|
볼륨(24시간):